Barriers to Biomarker Testing Implementation in Precision Oncology
Despite guidelines recommending broad molecular profiling for precision oncology, biomarker testing faces significant implementation barriers including insurance coverage limitations, lengthy turnaround times, and tissue adequacy issues. Studies show most patients lack biomarker results at initial consultation, with up to 43% having insufficient tissue for genotyping in NSCLC cases.
Precision oncology depends on biomarker testing, with guidelines now recommending broad molecular profiling across multiple tumor types, yet significant barriers persist in clinical implementation. Oncologists report that testing rates remain inconsistent across settings, payers, and disease stages, creating a gap between guidelines and clinical practice.
The most persistent barriers to guideline-recommended biomarker testing are turnaround time, cost, and tissue adequacy. In advanced disease, clinicians often start therapy before full molecular results are in, as next-generation sequencing panels often require 10 to 21 days in routine practice. A 2024 community hospital study in Canada among patients with NSCLC found that 79.7% of patients still did not have core biomarker results available at the time of medical oncology consultation.
The biggest barrier to testing is insurance coverage, as not every insurance routinely covers testing, and some only cover testing on tissue and not on blood. Comprehensive molecular profiling is resource-intensive, and results are only as good as the sample quality, which can be compromised by staining artifacts or degradation. There's also an underappreciated issue of sampling error: a single biopsy may not capture the full biological complexity of a heterogeneous tumor, meaning treatment decisions may be based on an incomplete picture.
Insufficient tissue remains a frequent issue, with small biopsies, especially in lung cancer, limiting the ability to run broad panels. A report among patients with NSCLC found that up to 43% had insufficient tissue for genotyping; the reasons included biopsy not being able to be performed safely, limited sampling, or inability to obtain adequate tissue. Interventional radiology capacity and procedural risk add another layer, and in frail patients, repeat biopsy is not always feasible.
Liquid biopsy offers faster turnaround, but sensitivity varies by tumor burden and shedding. Oncologists are showing enthusiasm for how recent FDA decisions are shaping treatment sequencing, biomarker testing, or patient selection in their everyday practice. Having access to methods to sequence specific targets is critical for considering re-treatment with agents directed at those targets, and as genomic testing becomes more standard, clinicians will learn more about how to better sequence therapies or combine them to improve outcomes, especially among high-risk patients.